Viral serology after bone marrow transplantation

Area of Science:

• Immunology
• Virology
• Hematology

Background:

• Bone marrow transplantation (BMT) is a critical procedure for various hematologic and oncologic conditions.
• Serostatus for herpes group viruses can change post-BMT, impacting patient management.
• Herpesvirus reactivation poses significant risks in immunocompromised BMT recipients.

Purpose of the Study:

• To investigate the frequency of herpesvirus serostatus conversion in bone marrow transplant recipients.
• To assess the clinical implications of herpesvirus serostatus changes after BMT.
• To evaluate the utility of post-transplant serological testing for herpesviruses.

Main Methods:

• Retrospective review of 68 bone marrow transplant patient records from a 1-year period.
• Serological assessment using complement fixation and ELISA for herpes group viruses (VZV, CMV, HSV).
• Analysis of serostatus at pre-transplant, early post-transplant (days 20-35), and late post-transplant (>100 days) time points.

Main Results:

• Limited data available for comprehensive analysis (only 7 patients with complete serostatus data).
• Observed seroconversion from positive to negative for anti-VZV (1 patient, developed chickenpox) and anti-CMV (1 patient, donor was anti-CMV negative).
• Some seronegative recipients of seropositive donor marrow developed antibodies; notable changes in anti-HSV antibody levels were associated with viral shedding.

Conclusions:

• Herpesvirus serostatus in bone marrow transplant recipients frequently changes post-transplant.
• Repeat serological testing after BMT is essential for guiding antiviral prophylaxis strategies.
• Post-transplant herpesvirus serostatus monitoring aids in the timely diagnosis of clinical disease and management of complications.